SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?

Adv Drug Deliv Rev. 2021 May:172:314-338. doi: 10.1016/j.addr.2021.01.014. Epub 2021 Jan 20.

Abstract

The ongoing SARS-CoV-2 pandemic has led to the focused application of resources and scientific expertise toward the goal of developing investigational vaccines to prevent COVID-19. The highly collaborative global efforts by private industry, governments and non-governmental organizations have resulted in a number of SARS-CoV-2 vaccine candidates moving to Phase III trials in a period of only months since the start of the pandemic. In this review, we provide an overview of the preclinical and clinical data on SARS-CoV-2 vaccines that are currently in Phase III clinical trials and in few cases authorized for emergency use. We further discuss relevant vaccine platforms and provide a discussion of SARS-CoV-2 antigens that may be targeted to increase the breadth and durability of vaccine responses.

Keywords: COVID-19; ORF3a; Phase III vaccine trials; Pre-fusion S protein; SARS-CoV-2 vaccine; Vaccine platform.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • COVID-19 / epidemiology
  • COVID-19 / immunology
  • COVID-19 / prevention & control*
  • COVID-19 Vaccines / administration & dosage*
  • COVID-19 Vaccines / chemistry
  • COVID-19 Vaccines / immunology
  • Clinical Trials, Phase III as Topic / methods*
  • Drug Evaluation, Preclinical / methods
  • Drug Evaluation, Preclinical / trends
  • Humans
  • Protein Structure, Secondary
  • Protein Structure, Tertiary
  • SARS-CoV-2 / chemistry
  • SARS-CoV-2 / drug effects*
  • SARS-CoV-2 / immunology

Substances

  • COVID-19 Vaccines